Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | EED | O75530 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20138442 | 0.99 | SLC6A2 (0.48) | SLC6A2SLC6A4CYP2D6SLC6A3EED | |
| SCHEMBL25525962 | 0.89 | TAAR1 (0.50) | GRIN2BTAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL5343612 | 0.85 | MEN1 (0.50) | SLC6A2SLC6A4GRIN2BTAAR1IDO1 | |
| SCHEMBL12952359 | 0.82 | AKT2 (0.52) | SLC6A2SLC6A4CYP2D6SLC6A3EED | |
| SCHEMBL7285603 | 0.81 | ALDH1A1 (0.43) | SLC6A2GRIN2BADRB1IDO1SIGMAR1 | |
| SCHEMBL4825172 | 0.80 | SSTR4 (0.44) | SLC6A2SLC6A4SLC6A3ADRB1TAAR1 | |
| SCHEMBL15056947 | 0.80 | TAAR1 (0.49) | SLC6A2SLC6A4CYP2D6SLC6A3EED | |
| SCHEMBL20147389 | 0.79 | LMNA (0.51) | SLC6A4GRIN2BTAAR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL20137865 | 0.79 | SSTR4 (0.43) | SLC6A2SLC6A4SLC6A3ADRB1TAAR1 | |
| Hydrochloric Acid SCHEMBL29971297 | 0.79 | SSTR4 (0.43) | SLC6A2SLC6A4SLC6A3ADRB1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885CYP2D6 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.